Trials / Completed
CompletedNCT04555525
A Pilot Study on the Use of Seysara for Rosacea
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Derm Research, PLLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sarecycline | sarecycline tablet |
| DIETARY_SUPPLEMENT | Centrum Adult Multivitamin | Centrum Adult Mulltivitamin tablet |
Timeline
- Start date
- 2019-04-15
- Primary completion
- 2020-09-23
- Completion
- 2020-10-01
- First posted
- 2020-09-18
- Last updated
- 2021-01-07
- Results posted
- 2020-12-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04555525. Inclusion in this directory is not an endorsement.